(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 April 2013 (11.04.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/052507 A1

(51) International Patent Classification:
*A61K 48/00* (2006.01) *A61P 3/04* (2006.01)
*A61K 38/17* (2006.01) *A61P 3/00* (2006.01)
*A61K 38/16* (2006.01)

(21) International Application Number:
PCT/US2012/058495

(22) International Filing Date:
2 October 2012 (02.10.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/542,751 3 October 2011 (03.10.2011) US

(71) Applicants: **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; 1111 Franklin Street 11th Floor, Oakland, CA 94607 (US). **KINETA ONE, LLC** [US/US]; Washington Limited Liability Company, 219 Terry Avenue North, Suite 300, Seattle, WA 98109 (US).

(72) Inventors: **CHANDY, George, K.**; 1219 Morning Side Drive, Laguna Beach, CA 92651 (US). **UPADHAYAY, Sanjeev, Kumar**; 1140 Stanford, Irvine, CA 92612 (US). **WANG, Ping, H.**; 27 Harcourt, Newport Coast, CA 92657 (US). **CORSI, Paolo, Sassone**; 960 Baja Street, Laguna Beach, CA 92651 (US). **MAHAN, Kristin, Lynn-Eckel**; 2013 Los Trancos Ave., Irvine, CA 92617 (US). **IADONATO, Shawn**; 6629 Holly Pl SW, Seattle, WA 98136 (US). **MUKERGEE, Joseph**; 27 Exploration, Irvine, CA 92618 (US). **MIRBOLOOKI, Reza, M.**; 3063 Chapman Ave. 2417, Orange, CA 92868 (US).

(74) Agent: **BUYAN, Robert, D.**; Stout, Uxa, Buyan & Mullins, LLP., 4 Venture Suite 300, Irvine, CA 92618 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published**:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2013/052507 A1

(54) Title: TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS

(57) Abstract: Activation of brown adipose tissue, treatment of obesity and/or treatment of obesity-related disorders in human or non-human animal subjects by administering to the subject a potassium channel inhibiting agent. The potassium channel inhibiting agent may comprise ShK toxin or a modified ShK toxin. Examples of modified ShK toxins include ShK-186.